Response Genetics, Inc. to Release Second Quarter 2008 Financial Results

LOS ANGELES--(BUSINESS WIRE)--Response Genetics, Inc. (Nasdaq: RGDX), a company focused on the development and commercialization of molecular diagnostic tests for cancer, will announce second quarter 2008 financial results Tuesday, August 12 after close of market.

About Response Genetics, Inc.

Response Genetics, Inc. ("RGI"; the “Company”) (Nasdaq: RGDX) is engaged in the research and development of pharmacogenomic cancer diagnostic tests based on its proprietary and patented technologies. RGI's technologies enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed, paraffin-embedded specimens. RGI currently generates revenue primarily from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The Company was founded in 1999, and its principal headquarters are located in Los Angeles. For more information, please visit www.responsegenetics.com.

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and the statements of representatives of RGI related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, business strategy planning, expectations and intentions, such as the ability of the Company to analyze cancer samples, the potential to develop additional diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, the ability of the Company to broaden the commercialization of its ResponseDx:Lung™ and ResponseDX:Colon™ tests, and other statements identified by words such as "projects," "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans" or similar expressions.

These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.

Investor Relations:
Trout Group
Peter Rahmer, 646-272-8526
or
Media Relations:
Fleishman-Hillard
Barry Sudbeck, 415-318-4261